Investment analysts at StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
A number of other brokerages have also commented on ALIM. HC Wainwright decreased their price objective on Alimera Sciences from $9.00 to $5.00 in a report on Friday, May 19th. Craig Hallum decreased their price objective on Alimera Sciences from $18.00 to $8.00 in a report on Monday, April 3rd.
Alimera Sciences Stock Performance
Shares of ALIM opened at $2.35 on Wednesday. The stock has a 50 day moving average price of $1.90 and a two-hundred day moving average price of $2.55. The firm has a market capitalization of $17.39 million, a P/E ratio of -0.96 and a beta of 1.38. Alimera Sciences has a 52 week low of $1.30 and a 52 week high of $7.92.
Hedge Funds Weigh In On Alimera Sciences
Institutional investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new position in Alimera Sciences in the fourth quarter valued at approximately $32,000. Susquehanna International Group LLP purchased a new stake in shares of Alimera Sciences during the fourth quarter worth $92,000. Renaissance Technologies LLC lifted its position in shares of Alimera Sciences by 2.3% during the second quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock worth $698,000 after acquiring an additional 2,900 shares in the last quarter. Finally, Caligan Partners LP purchased a new stake in shares of Alimera Sciences during the fourth quarter worth $1,297,000. Hedge funds and other institutional investors own 24.58% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.